Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 8 Head and Neck Neoplasms 3 Carcinoma, Squamous Cell 3 Thyroid Neoplasms 1 Smoking 1 Ovarian Neoplasms 1 Nasopharyngeal Carcinoma 1 Laryngeal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1

Interventions

Cisplatin 127 Gemcitabine 71 Radiotherapy, Intensity-Modulated 61 toripalimab 39 Capecitabine 37 Docetaxel 36 Fluorouracil 35 Radiotherapy 24 camrelizumab 23 Drug Therapy 22 nimotuzumab 18 spartalizumab 13 pembrolizumab 13 nedaplatin 12 Chemoradiotherapy 12 sintilimab 11 apatinib 11 Induction Chemotherapy 11 Immune Checkpoint Inhibitors 11 tislelizumab 10 Nivolumab 10 Magnetic Resonance Spectroscopy 10 Specimen Handling 9 Radiation 9 Cetuximab 9 Carboplatin 9 endostar protein 8 Paclitaxel 8 Bevacizumab 8 anlotinib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Nasopharyngeal Carcinoma × olaparib × Head & Neck × Clear all

NCT04825990 2026-06-01

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡